Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2017 /
Circulating tumour cells may predict late recurrence in HR-positive breast cancer patients

5th - 9th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.12.17
Views: 827

Dr Joseph Sparano - Albert Einstein Cancer Center, New York, USA

Dr Joseph Sparano speaks at a SABCS 2017 press session about how his findings show that a single positive CTC assay result five years after diagnosis provides independent prognostic information for late recurrence.

Among patients with hormone receptor (HR)-positive HER2-negative stage 2-3 breast cancer without clinical evidence of recurrence, those who had circulating tumour cells (CTC) detected in blood five years after diagnosis had an increased risk for late recurrence of breast cancer.

Read the news story for more. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation